|
|
|
| The World Patient Safety Congress Americas (formerly known as World Drug Safety Congress Americas) returns to the Thomas M.Menino Convention & Exhibition Center, Boston from October 13-15, 2026. This premier event brings together over 1,800 leaders from pharma, biotech, and regulatory bodies to explore the future of pharmacovigilance. With a focus on AI, automation, and patient-centricity, the congress provides a vital platform for industry experts to share innovative strategies and ensure safety excellence across pharmaceutical drugs and medical devices. |
|
|
|
|
By Ray Dogum, Chief Editor, Drug Discovery Online | Spatial multiomics offers extraordinary biological insight, but high costs, tissue bottlenecks, and unclear clinical relevance still limit its reach. | |
|
|
Why Rare Cancers Are Often Left Behind In Drug Discovery | By Paul Romness, chair, chief executive officer, president, OS Therapies | Combining advances in AI with continued investment in rare cancer research could help bring new treatment options to patients who currently have very few. |
|
|
GLP-1 Agonists In Addiction: Rationale And Drug Development | By Tariq M. Ghafoor, MD, medical director, Aurora Behavioral Healthcare, Tempe, Arizona; founder, Transitions Center and AddictionRehab.com | GLP-1 receptor agonists represent a scientifically credible and potentially consequential avenue in addiction medicine. |
|
|
|
|
|
| The Most Exciting Frontiers In Cell Therapy Development | Video | BD Biosciences | From high-dimensional profiling to customizable Omic panels, new technologies are redefining cell therapy development—delivering better insights, efficiency, and scalability for researchers worldwide. |
|
|
|
| A Human-Relevant Model Of The Liver Sinusoid | Application Note | Emulate | This organ-on-a-chip model minimizes drug absorption while maintaining the essential architecture. Examine the specifications of this product engineered to model the human liver. |
|
|
|
|
|
|
|
